Carperitide (alpha-human atrial natriuretic peptide) improves systemic hemodynamics in patients with heart failure through a vasodilatory action, a natriuretic action, and inhibition of the renin-angiotensin-aldosterone system and has been widely-used in Japan. However, a paucity of report is available on the effects of carperitide on short and long-term prognosis in patients with both cardiac and renal failure. The purpose of this study is to evaluate the effects of carperitide therapy on short and long-term prognosis in patients with both cardiac and renal failure, in comparison with standard therapy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
200
carperitide(alpha-human atrial natriuretic peptide, 0.025-0.05μg/kg/min)
Loop diuretics, Aldosterone blockers, Beta blockers, ACE inhibitors, Angiotensin receptor blockers, Nitrates, digitalis
First Department of Internal Medicine, Nara Medical University
Nara, Japan
Unexpected rehospitalization for cardiovascular events, uremic symptom, initiation of maintenance dialysis, and kidney transplantation
Time frame: at 6 months and 2 years
All cause mortality
Time frame: at discharge, 6 months, and 2 years
Sudden death
Time frame: at discharge, 6 months, and 2 years
Cardiovascular death
Time frame: at discharge, 6 months, and 2 years
Plasma B-type natriuretic peptide concentration
Time frame: at discharge, 6 months, and 2 years
Estimated GFR
Time frame: at discharge, 6 months, and 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.